Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Iressa 2nd Line Phase III Study in Japan

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00252707
First received: November 14, 2005
Last updated: December 14, 2007
Last verified: December 2007